Literature DB >> 20886632

Surgical treatment of breast cancer among the elderly in the United States.

Amy K Alderman1, Julie Bynum, Jason Sutherland, Nancy Birkmeyer, E Dale Collins, John Birkmeyer.   

Abstract

BACKGROUND: Breast-conserving therapy (BCT) has emerged as the preferred treatment for most women with early stage breast cancer. However, there is concern for underuse in the elderly, with previously documented low rates of BCT and large variations in practice patterns. The authors' purpose was to examine patterns and correlates of BCT for breast cancer in the elderly US population.
METHODS: The primary outcome was receipt of BCT. The 2003 to 2004 Medicare inpatient, outpatient, and carrier files were used to identify incident breast cancer patients and the American Medical Association to ascertain surgeon information. The primary independent variables were US state where treatment was performed along with patient and surgeon sociodemographic information. Multivariate logistic regression was used for the analyses.
RESULTS: BCT was performed in 81.8% of patients (N = 20,032). Variation in use of BCT across states was low, ranging from 74.2% in Utah to 84.0% in New Mexico. Several factors were significantly associated with low use of BCT: advanced patient age (>85 vs <70 years: odds ratio [OR], 0.50; 95% confidence interval [CI], 0.42-0.59); comorbidities (>3 vs ≤ 3: OR, 0.26; 95% CI, 0.24-0.28), and low socioeconomic status (SES) (lowest quintile vs highest quintile SES: OR, 0.60; 95% CI, 0.52-0.68). Variation in use of BCT by surgeon was low, although female surgeons aged 40 to 49 years and ≥ 60 years had significantly higher use compared with younger men.
CONCLUSIONS: BCT has become the primary management among elderly breast cancer patients. Despite earlier studies to the contrary, there is now little variation in BCT use among Medicare patients.
Copyright © 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 20886632     DOI: 10.1002/cncr.25617

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Socioeconomic disparities in breast cancer treatment among older women.

Authors:  Arica White; Lisa C Richardson; Helen Krontiras; Maria Pisu
Journal:  J Womens Health (Larchmt)       Date:  2013-12-19       Impact factor: 2.681

2.  Do socially deprived urban areas have lesser supplies of cancer care services?

Authors:  Elizabeth B Lamont; Yulei He; S V Subramanian; Alan M Zaslavsky
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

3.  Current status of diagnosis and treatment of primary breast cancer in beijing, 2008.

Authors:  Xiao-Mei Yuan; Ning Wang; Tao Ouyang; Lei Yang; Ming-Yang Song; Ben-Yao Lin; Yun-Tao Xie; Jin-Feng Li; Kai-Feng Pan; Wei-Cheng You; Lian Zhang
Journal:  Chin J Cancer Res       Date:  2011-03       Impact factor: 5.087

4.  Treatment variation in patients diagnosed with early stage breast cancer in Alberta from 2002 to 2010: a population-based study.

Authors:  Stacey Fisher; He Gao; Yutaka Yasui; Kelly Dabbs; Marcy Winget
Journal:  BMC Health Serv Res       Date:  2015-01-22       Impact factor: 2.655

Review 5.  Socioeconomic status and breast cancer treatment.

Authors:  Marie S Dreyer; Ann B Nattinger; Emily L McGinley; Liliana E Pezzin
Journal:  Breast Cancer Res Treat       Date:  2017-09-07       Impact factor: 4.624

6.  Breast-Contour-Preserving Procedure as a Multidisciplinary Parameter of Esthetic Outcome in Breast Cancer Treatment in The Netherlands.

Authors:  Annnelotte van Bommel; Pauline Spronk; Marc Mureau; Sabine Siesling; Carolien Smorenburg; Rob Tollenaar; Marie-Jeanne Vrancken Peeters; Thijs van Dalen
Journal:  Ann Surg Oncol       Date:  2019-03-04       Impact factor: 5.344

Review 7.  Older breast cancer undertreatment: unconscious bias to undertreat-potential role for the international geriatric radiotherapy group?

Authors:  Nam P Nguyen; Ulf Karlsson; Eromosele Oboite; Julio Alvarenga; Juan Godinez; Alice Zamagni; Micaela Motta; Satya Bose; Vincent Vinh-Hung
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.